Strategies for the prevention and treatment of statin-induced myopathy: Is there a role for ubiquinone supplementation?

American Journal of Health-System Pharmacy

Volumn 61, Issue 5, 2004, Pages 515-519

  Koumis, Tina ^a,c   Nathan, Joseph P ^b   Rosenberg, Jack M ^a   Cicero, Lorraine A ^c  

^a Intl Drug Information Center   (United States)

^b Department of Pharmacy Practice ^*  (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEFAZODONE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; UBIDECARENONE; UBIQGEL; UBIQUINONE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROTIC PLAQUE; CASE REPORT; CONGESTIVE HEART FAILURE; DIET SUPPLEMENTATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIZZINESS; DRUG FORMULATION; DRUG LABELING; DRUG MARKETING; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ELECTRON TRANSPORT; FAMILIAL HYPERLIPEMIA; FEMALE; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; KEARNS SAYRE SYNDROME; MALE; MEDLINE; MELAS SYNDROME; MERRF SYNDROME; MYOPATHY; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PATIENT EDUCATION; PERIODONTAL DISEASE; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 1542377656     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.5.515     Document Type: Review

References (40)

1. Business Week online. AstraZeneca's future may rest on mere milligrams. FDA dosage restrictions could crimp its promising Crestor. www.businessweek.com/magazine/content/02_25/b3788135.htm (accessed 2002 Nov 27).
2. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001:971-1002.
3. McFarlane SI, Muniyappa R, Francisco R et al. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87:1451-8.
4. Drug Facts and Comparisons. HMG-CoA reductase inhibitors. eFacts online. Available from Wolters Kluwer Health, Inc. (accessed 2003 Mar 28).
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7-22.
6. Richard AA, Harrison TM. Efficacy of HMG-CoA reductase inhibitors in treating osteoporosis. Am J Health-Syst Pharm. 2002; 59:372-7.
7. Cushenberry LM, de Bittner MR. Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann Pharmacother. 2002; 36:671-8.
8. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002; 40:67-73.
9. Buemi M, Allegra A, Corica F et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther. 2000; 67:427-31.
10. Jick H, Zornberg GL, Jick SS et al. Statins and the risk of dementia. Lancet. 2000; 356:1627-31. [Erratum, Lancet. 2001; 357: 562.]
11. Jick H, Zornberg GL, Jick SS et al. Statins and the risk of dementia. Lancet. 2000; 356:1627-31. [Erratum, Lancet. 2001; 357: 562.]
12. Wolozin B, Kellman W, Ruosseau P et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000; 57:1439-43.
13. Raggatt LJ, Partridge NC. HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs. 2002; 62:2185-91.
14. Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-β lb in MS. Neurology. 2002; 59:990-7.
15. Thibault A, Samid D, Tompkins AC et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996; 2:483-91.
16. Kim WS, Kim MM, Choi HJ et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs. 2001; 19:81-3.
17. White CM. HMG CoA reductase inhibitor-induced muscle toxicity: risks, monitoring, and management. Formulary. 2002; 37:583-8.
18. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med. 2002; 137:617-8. Editorial.
19. USP dispensing information for the healthcare professional. 22nd ed. Greenwood Village, CO: Micromedex Thompson Healthcare; 2002.
20. Gaist D, Jeppesen U, Andersen M et al. Statins and risk of polyneuropathy: a case-control study. Neurology. 2002; 58:1333-7.
21. Farmer JA. Learning from the cerivastatin experience. Lancet. 2001; 358:1383-5.
22. Folkers K, Langsjoen P, Willis R et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci. 1990; 87: 8931-4.
23. Laaksonen R, Ojala JP, Tikkanen MJ et al. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1994; 46:313-7.
24. De Pinieux G, Chariot P, Ammi-Said M et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996; 42:333-7.
25. Laaksonen R, Jokelainen K, Laakso J et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 1996; 77:851-4.
26. Laaksonen R, Jokelainen K, Sahi T et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995; 57:62-6.
27. Hendler SS, Rorvik D. PDR for nutritional supplements. Montvale, NJ: Medical Economics; 2001:103-6.
28. Jellin JM, Gregory PJ, Batz F et al. Pharmacist's letter/prescriber's letter natural medicines comprehensive database. 5th ed. Stockton, CA: Therapeutic Research Faculty; 2003:379-82.
29. Wollschlaeger B. Commentary: statin drugs and coenzyme Q10. A potential for drug induced nutrient depletion. www. thyroid-info.com/articles/coq10.htm (accessed 2003 Mar 28).
30. Langsjoen PH. Statin-induced cardiomyopathy: introduction to the citizen's petition on statins. www.redflagsweekly.com/features/2002_july08P. html (accessed 2003 Mar 28).
31. Better Life Institute. Coenzyme Q10 & statins. www.blionline.com/hdb/docs/coenzymeq10andstatins.htm (accessed 2003 Mar 28).
32. Raj SR, Weisel RD, Verma S. Coenzyme Q10 and congestive heart failure: what is the verdict? Can J Cardiol. 2002; 18:1054-8.
33. Food and Drug Administration. Citizen petition to change the labeling for all statin drugs (Mevacor, Lescol, Pravachol, Zocor, Lipitor, and Advicor) recommending use of 100-200mg per day of supplemental co-enzyme Q10 to reduce the risk of statin-induced myopathies (including cardiomyopathy and congestive heart failure). www.fda.gov/ohrms/dockets/dailys/02/May02/052902/02p-0244-cp00001-01-vol1.pdf (accessed 2003 Mar 28).
34. Woodcock J, Center for Drug Evaluation and Research. (Letter to Whitaker JM, Emord & Associates.) www.fda.gov/ohrms/dockets/dallys/02/Nov02/112202/02p-0243-let0001-vol1.pdf (accessed 2003 Mar 28).
35. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl JMed. 1995; 333:664-5. Letter.
36. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet. 1989; 2:1097-8. Letter.
37. Chariot P, Abadia R, Agnus D et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993; 94:109-10.
38. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002; 40:567-72.
39. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 2001; 35: 1096-107.
40. Phillips PS, Haas RH, Bannykh S et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002; 137:581-5.